Drug intelligence / Profile preview

[68Ga]Ga-DOTA-CAIX peptide

Development stage: Unknown
Lead developer: Union Hospital of Huazhong University of Science and Technology
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

[68Ga]Ga-DOTA-CAIX peptide is a gallium-68 labeled radiopharmaceutical developed by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology for the diagnostic imaging of renal cell carcinoma (RCC). The agent consists of a peptide ligand that specifically targets Carbonic Anhydrase IX (CAIX), a cell-surface enzyme that is significantly overexpressed in clear cell renal cell carcinoma but has minimal expression in normal tissues. By utilizing the DOTA chelator to complex the positron-emitting isotope Gallium-68, the peptide enables high-sensitivity Positron Emission Tomography (PET) imaging. This allows for the non-invasive detection, staging, and assessment of tumor burden in patients with suspected or confirmed RCC, as well as the evaluation of CAIX expression levels to guide treatment strategies.

Other names: 68Ga-DOTA-CAIX peptideGa-68 DOTA-CAIXGa68 DOTA-CAIXGa 68 DOTA-CAIX[68Ga]Ga-DOTA-CAIX peptide-Union Hospital, Tongji Medical College, Huazhong University of Science and Technology-renal cell carcinoma

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on [68Ga]Ga-DOTA-CAIX peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [68Ga]Ga-DOTA-CAIX peptide.

Explore the full profile